Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Plasmaglob 10 gm Injection 100 ml: Enhancing Immune Response
Introduction:
Plasmaglob 10 gm Injection 100 ml falls under the category of immunizing agents, specifically addressing immunoglobulin (antibody) deficiencies and certain inflammatory disorders. It proves efficacious in treating immunoglobulin deficiencies in individuals with primary immunodeficiencies (PID) present from birth and secondary immunodeficiency (SID) developed later in life. Additionally, Plasmaglob 10 gm Injection 100 ml is employed for addressing inflammatory disorders such as primary immune thrombocytopenia, Guillain-Barre syndrome, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy.
Uses of Plasmaglob 10 gm Injection 100 ml:
This injection serves a versatile role in medical intervention, catering to immunoglobulin deficiency and inflammatory conditions, including primary immune thrombocytopenia, Guillain-Barre syndrome, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.
Therapeutic Benefits:
Plasmaglob 10 gm Injection 100 ml operates by replenishing deficient antibodies crucial for combating infections and inflammation. Its mechanism closely mirrors the action of naturally occurring immunoglobulins within the body. These immunoglobulins play a pivotal role in the immune system, recognizing antigens or foreign elements and facilitating their elimination. The injection is particularly instrumental in treating immunoglobulin deficiencies, whether congenital (PID) or acquired later in life (SID). Furthermore, it extends its therapeutic reach to address inflammatory disorders, ranging from temporary peripheral nerve inflammation causing weakness in legs and arms (Guillain-Barre syndrome) to conditions like Kawasaki disease and chronic inflammatory demyelinating polyneuropathy.